Adamas Pharmaceuticals (ADMS) Misses Q3 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Adamas Pharmaceuticals (ADMS) Misses Q3 EPS by 13c

Adamas Reports Third Quarter 2014 Financial Results

November 4, 2014 4:03 PM EST

EMERYVILLE, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.

"We continue to advance ADS-5102, our lead wholly-owned product candidate, through pivotal clinical trials," said Gregory T. Went, Ph.D., Chairman and Chief Executive... More